Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 213619, held by Pharmazone. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 213619 (Triamcinolone Acetonide), held by Pharmazone, was first approved by FDA on Nov 10, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Ointment, USP 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.05% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
